Qiu-Chuan Zhuang

机构：Viva Biotech (China)

发表论文 11 篇 · 总被引 972 次 · h-index 9

代表论文

A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma (2018 · Journal of Hematology & Oncology · 被引 539)
Management of cytokine release syndrome related to CAR-T cell therapy (2019 · Frontiers of Medicine · 被引 107)
Long-Term Follow-up of a Phase 1, First-in-Human Open-Label Study of LCAR-B38M, a Structurally Differentiated Chimeric Antigen Receptor T (CAR-T) Cell Therapy Targeting B-Cell Maturation Antigen (BCMA), in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM) (2019 · Blood · 被引 94)
Durable remissions with BCMA-specific chimeric antigen receptor (CAR)-modified T cells in patients with refractory/relapsed multiple myeloma. (2017 · Journal of Clinical Oncology · 被引 81)
Durable remissions with BCMA-specific chimeric antigen receptor (CAR)-modified T cells in patients with refractory/relapsed multiple myeloma. (2017 · Journal of Clinical Oncology · 被引 67)
Updated Analysis of a Phase 1, Open-Label Study of LCAR-B38M, a Chimeric Antigen Receptor T Cell Therapy Directed Against B-Cell Maturation Antigen, in Patients with Relapsed/Refractory Multiple Myeloma (2018 · Blood · 被引 42)